| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8786701 | European Journal of Surgical Oncology (EJSO) | 2018 | 21 Pages |
Abstract
The morbidity of rectosigmoid resection during cytoreductive surgery for ovarian cancer seems acceptable. Ileostomy does not seem associated with a lower risk of major complications or adjuvant bevacizumab with a higher complication rate.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
M. Fournier, C. Huchon, C. Ngo, C. Bensaid, A.S. Bats, P. Combe, M.A. le FrèreBelda, L. Fournier, A. Berger, F. Lecuru,